Literature DB >> 23418798

Parkinson disease: an update.

John D Gazewood1, D Roxanne Richards, Karl Clebak.   

Abstract

Parkinson disease is a progressive neurologic disorder afflicting approximately 1 percent of Americans older than 60 years. The cardinal features of Parkinson disease are bradykinesia, rigidity, tremor, and postural instability. There are a number of neurologic conditions that mimic the disease, making it difficult to diagnose in its early stages. Physicians who rarely diagnose Parkinson disease should refer patients suspected of having it to physicians with more experience in making the diagnosis, and should periodically reevaluate the accuracy of the diagnosis. Treatment is effective in reducing motor impairment and disability, and should be started when a patient begins to experience functional impairment. The combination of carbidopa and levodopa is the most effective treatment, but dopamine agonists and monoamine oxidase-B inhibitors are also effective, and are less likely to cause dyskinesias. For patients taking carbidopa/levodopa who have motor complications, adjunctive therapy with a dopamine agonist, a monoamine oxidase-B inhibitor, or a catechol O-methyltransferase inhibitor will improve motor symptoms and functional status, but with an increase in dyskinesias. Deep brain stimulation is effective in patients who have poorly controlled symptoms despite optimal medical therapy. Occupational, physical, and speech therapy improve patient function. Fatigue, sleep disturbances, dementia, and depression are common in patients with Parkinson disease. Although these conditions are associated with significantly lower quality of life, they may improve with treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23418798

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  38 in total

1.  Survival, differentiation, and neuroprotective mechanisms of human stem cells complexed with neurotrophin-3-releasing pharmacologically active microcarriers in an ex vivo model of Parkinson's disease.

Authors:  Nicolas Daviaud; Elisa Garbayo; Laurence Sindji; Alberto Martínez-Serrano; Paul C Schiller; Claudia N Montero-Menei
Journal:  Stem Cells Transl Med       Date:  2015-04-29       Impact factor: 6.940

Review 2.  Oxidative stress, redox signalling and endothelial dysfunction in ageing-related neurodegenerative diseases: a role of NADPH oxidase 2.

Authors:  Sarah Cahill-Smith; Jian-Mei Li
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

3.  Chronic Mild Gut Inflammation Accelerates Brain Neuropathology and Motor Dysfunction in α-Synuclein Mutant Mice.

Authors:  Yuki Kishimoto; Wandi Zhu; Waki Hosoda; Jyoti M Sen; Mark P Mattson
Journal:  Neuromolecular Med       Date:  2019-05-11       Impact factor: 3.843

Review 4.  Creatine as a Neuroprotector: an Actor that Can Play Many Parts.

Authors:  Eduardo Peil Marques; Angela T S Wyse
Journal:  Neurotox Res       Date:  2019-05-08       Impact factor: 3.911

5.  Mapping the alterations in glutamate with GluCEST MRI in a mouse model of dopamine deficiency.

Authors:  Puneet Bagga; Rachelle Crescenzi; Guruprasad Krishnamoorthy; Gaurav Verma; Ravi Prakash Reddy Nanga; Damodar Reddy; Joel Greenberg; John A Detre; Hari Hariharan; Ravinder Reddy
Journal:  J Neurochem       Date:  2016-10-16       Impact factor: 5.372

6.  The correlation between Toxoplasma gondii infection and Parkinson's disease: a case-control study.

Authors:  Mahmoud Mahami Oskouei; Faezeh Hamidi; Mahnaz Talebi; Mehdi Farhoudi; Ali Akbar Taheraghdam; Tohid Kazemi; Homayoun Sadeghi-Bazargani; Esmaeil Fallah
Journal:  J Parasit Dis       Date:  2014-10-14

7.  Parkinson's disease impairs masticatory function.

Authors:  Giselle Rodrigues Ribeiro; Camila Heitor Campos; Renata Cunha Matheus Rodrigues Garcia
Journal:  Clin Oral Investig       Date:  2016-06-13       Impact factor: 3.573

8.  Modeling nigrostriatal degeneration in organotypic cultures, a new ex vivo model of Parkinson's disease.

Authors:  N Daviaud; E Garbayo; N Lautram; F Franconi; L Lemaire; M Perez-Pinzon; C N Montero-Menei
Journal:  Neuroscience       Date:  2013-10-23       Impact factor: 3.590

Review 9.  Pedunculopontine Nucleus Deep Brain Stimulation Improves Gait Disorder in Parkinson's Disease: A Systematic Review and Meta-analysis.

Authors:  Fabin Lin; Dihang Wu; Chenxin Lin; Huihui Cai; Lina Chen; Guofa Cai; Qinyong Ye; Guoen Cai
Journal:  Neurochem Res       Date:  2020-01-16       Impact factor: 3.996

Review 10.  Paraoxonase 1 in neurological disorders.

Authors:  Teresita Menini; Alejandro Gugliucci
Journal:  Redox Rep       Date:  2013-11-12       Impact factor: 4.412

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.